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Abstract 11 
In the face of growing antimicrobial resistance, there is an urgent need for the development of 12 
effective strategies to target Pseudomonas aeruginosa. This metabolically versatile bacterium 13 
can cause a wide range of severe opportunistic infections in patients with serious underlying 14 
medical conditions, such as those with burns, surgical wounds or people with cystic 15 
fibrosis. Many of the key adaptations which arise in this organism during infection are centered 16 
on core metabolism and virulence factor synthesis. Interfering with these processes may 17 
provide a new strategy to combat infection, in combination with conventional antibiotics. This 18 
review will provide an overview of the most recent work which has advanced our 19 
understanding of P. aeruginosa infection. Strategies which exploit this recent knowledge to 20 
combat infection will be highlighted, alongside potential alternative therapeutic options and 21 
their limitations.   22 
23 
Introduction:  24 
Pseudomonas aeruginosa (Pa) is a prominent Gram-negative bacterial pathogen which can 25 
survive in a variety of challenging environments. Recent evidence suggests that Pa may be 26 
closely associated with human activity as it is rarely detected in pristine environments. Pa is a 27 
major cause of illness and mortality in humans. Infections exist across a spectrum which 28 
ranges from the acute to lifelong, persistent manifestations in patients with 29 
immunosuppressive or chronic conditions, such as cystic fibrosis (CF), burns, wounds and 30 
cancer [1,2]. Physicians and microbiologists have witnessed the increasing resistance of Pa 31 
to conventional therapies which are commonly use in the clinic. Drug design strategies for this 32 
organism have frequently hit a wall as compounds with high efficacy against laboratory strains 33 
frequently fail against clinical isolates. Dwindling profits and antimicrobial efficacy challenges 34 
have led to numerous pharmaceutical companies abandoning antibacterial drug discovery [3].  35 
The remarkable edge that Pa has over other human pathogens is difficult to pinpoint. However, 36 
it is thought to be mediated through a combination of the following overlapping characteristics: 37 
metabolic and phenotypic flexibility, prolific virulence factor production, persistence and a high 38 
intrinsic mutation rate [1]. Precisely how Pa coordinates the above systems at the site of 39 
human infection remains elusive. Comprehending how this organism accomplishes this feat 40 
is central to developing strategies to combat human infection. By furthering our understanding 41 
of the biology of Pa infection, we are more likely to expedite the development of new location-42 
specific strategies to combat infection and increase the efficacy of existing therapies. 43 
This review will provide an overview of the most recent developments which have advanced 44 
our understanding of Pa infection. Strategies which exploit this recent knowledge to combat 45 
infection will be highlighted, alongside current challenges and bottlenecks to future major 46 
advances.   47 
 48 
 49 
Current knowledge of Pa infection – latest tools of the trade 50 
What’s going on in-vivo?  51 
Advancements in omics and computing technologies over the last decade have led to an 52 
enormous leap in our understanding of acute and chronic Pa infection. High throughput 53 
genome sequencing allows for the direct inspection of the individual genomes for thousands 54 
of Pa isolates from diverse infection sites. This has facilitated the tracking of single strains 55 
over the course of an infection whilst also uncovering spatial and temporal heterogeneity, 56 
population structure, coexisting lineages, common SNPs, polymorphisms, and core genes. 57 
These recent advancements have also facilitated the examination of Pa megaplasmids and 58 
pangenomes [4–9].  59 
Sequencing advances have also allowed us to examine the transcriptional signature of Pa, 60 
along with other key pathogens, at the site of infection [10–12]. Developments in proteomics 61 
instrumentation and bacterial enrichment methods are also allowing us to examine at a subset 62 
of the Pa proteome from the infection site [13]. Most of the genomic and in-vivo/ex-vivo 63 
transcriptome investigations from human samples to date are from CF patients chronically 64 
infected with Pa. This bias towards respiratory samples compared with other infection sites is 65 
largely due to the relative availability of 1) fresh sputum (which can be collected non-invasively 66 
from CF patients) and 2) freshly explanted diseased lungs (which are removed prior to 67 
transplantation and dissected). Moving away from this trend, Cornforth et al. examined the Pa 68 
transcriptome from chronic wound and burn wound infection samples alongside Pa from CF 69 
sputum samples, providing a diverse sample set from patients treated with a variety of 70 
therapeutic regimens [10]. The above studies have allowed us to glean some core insights 71 
into Pa infection: 72 
 Pa infection is a spatially dynamic process with a convergent set of mutations evident 73 
over time in the population. Systems previously considered to be extremely important 74 
for infection are frequently mutated.  75 
 Despite lung containing genetically distinct populations, a common gene expression 76 
program is evident for chronic CF infection across multiple independent studies. This 77 
includes the downregulation of central metabolism, motility and amino acid 78 
biosynthesis. Systems to tolerate redox stress and micronutrient starvation are also 79 
activated. This suggests the existence of convergent phenotypes exist which serve to 80 
maximise Pa survival during infection.   81 
 The Pa transcriptome during human infection is distinct from in-vitro transcriptomes, 82 
despite a multitude of intrinsic differences such as infection site or therapeutic regimen.  83 
Using the above technologies, we bear witness to temporal Pa evolution and adaptation, 84 
uncovering genetic mutations accumulated over the course of human infection. We also get a 85 
snapshot of the final output of this dynamic process; the transcriptional/proteomic signature of 86 
infection. Thankfully, the above in-vivo data can be examined in the light of a vast repertoire 87 
of in-vitro functional genomics studies which have attempted to recapitulate the infection 88 
environment, and animal models of Pa infection. The combination of this knowledge with 89 
detailed mechanistic studies affords us the opportunity to cast the spotlight on effective new 90 
strategies with which to combat infection.  91 
Despite this extensive literature, we still struggle to fully interpret the above in-vivo omic data. 92 
This is because we have an elementary understanding of how several key pathways and 93 
systems operate in Pa. In fact, the core operations of several key Pa systems have been 94 
extrapolated from other bacteria, such as chemotaxis, central carbon metabolism, the electron 95 
transport chain (ETC), and redox tolerance. However, recent mechanistic studies are filling 96 
this knowledge gap [14–19]. The in-vivo transcriptomic studies have also highlighted several 97 
uncharacterised genes which appear to be expressed at a high level during the infection 98 
process. How do these uncharacterised nodes fit into the global picture of Pa infection? Our 99 
lack of an answer to this question alone demonstrates that we still have a lot to learn from in-100 
vitro mechanistic studies in order to fully comprehend Pa behaviour during infection.  101 
 102 
Supercharged Pa functional genomics – Transposon insertion sequencing 103 
Advances in sequencing technologies have been combined with traditional transposon 104 
mutagenesis by several research groups in a technique referred to as transposon sequencing 105 
(Tn-seq) (related strategies are known as TraDIS, INSeq, RB‐TnSeq and HITS). In this 106 
strategy, pooled populations of transposon mutants covering the entire genome are cultured 107 
in a selected environment. Sequencing tools are then used to pinpoint genomic regions which 108 
are important or essential for bacterial fitness [20]. When applied to Pa, this technique has 109 
facilitated the rapid identification of genes which are important for fitness in infection-relevant 110 
environments, single nutrient sources, energy limitation, antibiotic resistance, competing 111 
microorganisms, and motility [21–29]. This technique has also been combined with murine 112 
models of burn infection and chronic wound infection to determine the requirements of Pa in 113 
those environments [23,26].  114 
A comprehensive Tn-seq study (nine Pa strains grown on five different media) has highlighted 115 
the extensive genomic plasticity of Pa. For example, the type IV pilus-associated 116 
adhesin gene, pilY1, did not tolerate insertions in the lung isolate BWH013 when grown on LB 117 
medium whilst readily tolerating insertions in the other eight strains [24]. These recent in-vitro 118 
studies have provided excellent contextualisation of the human infection omics data. We now 119 
know which genes are important for fitness during growth in in-vivo-like environments, which 120 
genes are expressed in-vivo and which genes are frequently mutated during infection. This is 121 
important as gene expression changes don’t necessarily correlate with fitness during infection 122 
[23]. Using this information, we can put together a clear list of validated targets and strategies 123 
to disrupt Pa infection. 124 
New strategies to combat Pa infection 125 
All roads lead to metabolism: constraining the metabolic flexibility of Pa  126 
Many of the important changes in Pa which occur during infection rather than growth in 127 
standard laboratory conditions are centered on core metabolism. This includes the processes 128 
required for the acquisition of nutrients and for electron acceptors to fuel metabolism (Figure 129 
1 A-C). For this reason, the recent in-vivo transcriptomic/proteomic data has reignited interest 130 
in these processes. Although the metabolic versatility of Pa has been appreciated and studied 131 
for decades, recent work continues to transform our understanding of these systems and 132 
emphasize their importance during infection [30,31].  133 
Aerobic and anaerobic respiration have significant potential to be the cornerstone of future 134 
antimicrobial therapies targeting this organism. Pa possesses an extensively branched 135 
respiratory chain consisting of five terminal oxidases for aerobic respiration which it uses under 136 
different growth conditions (Figure 1B) [32]. This setup allows Pa to proliferate in host 137 
environments which contain variable levels of oxygen. The respiratory flexibility of Pa has 138 
been found to be even more extensive than originally thought due to the recent discovery of 139 
two ‘orphan’ terminal oxidase CcoN isosubunits - CcoN3 and CcoN4. These isosubunits are 140 
produced in response to nitrite and cyanide respectively. Remarkably, by interchanging with 141 
the integral cbb3-type cytochrome c oxidase subunits (encoded by ccoN1O1Q1P1 and 142 
ccoN2O2Q2P2), at least 16 active cytochrome oxidase subunit isoforms can be produced by 143 
Pa [33]. The CcoN4 subunit was subsequently shown to contribute to the reduction of 144 
phenazines (redox-sensitive small molecule metabolites that support redox balancing in Pa) 145 
and to virulence in a Caenorhabditis elegans model of infection [34]. The cbb3-type terminal 146 
oxidases also contribute to ciprofloxacin tolerance when phenazines are produced but not in 147 
a phenazine-null background, a key link between small molecule metabolites, primary 148 
metabolism, and antibiotics [35]. Indeed, phenazine production has been shown to affect Pa 149 
respiratory activity and terminal oxidase gene expression [36]. Furthermore, the challenge of 150 
Pa with sublethal concentrations of diverse antibiotics was shown to promote the accumulation 151 
of the phenazine pyocyanin (PYO), which in turn conferred general antibiotic tolerance. This 152 
phenomenon may be linked to the modulation of terminal oxidase expression by PYO [36,37]. 153 
This underscores the potential of terminal oxidases (and more generally, aerobic respiration) 154 
as a unique therapeutic target. 155 
Microenvironments of the CF lung comprising of static mucus are thought to be hypoxic or 156 
anaerobic. These low oxygen environments are unlikely to sustain aerobic respiration [38,39]. 157 
However, CF sputum contains 73 to 792 μM nitrate, which Pa utilises for growth through the 158 
sequential eight-electron reduction of NO3− to N2, a process known as denitrification (Figure 159 
1A) [40,41]. Anaerobic survival is also facilitated by pyruvate fermentation and phenazine 160 
antibiotics [42,43]. The transition of Pa to this anaerobic lifestyle is followed by a series of 161 
other key physiological alterations. These include the increased formation of cellular 162 
aggregations to shield itself from the surrounding environment (biofilms), slow growth, and a 163 
drastic modification of the structure and function of its lipopolysaccharide outer membrane. 164 
These changes imbue Pa with an enhanced resistance to host immune defences and to a 165 
series of antibiotics commonly used to treat infection [39,44,45]. For this reason, the efficacy 166 
of several bactericidal antibiotics such as ciprofloxacin is enhanced by the stimulation of 167 
aerobic respiration. As a lack of O2 increases the tolerance of Pa to antibiotics, the 168 
reoxygenation of O2-depleted biofilms should increase susceptibility to antibiotics by 169 
reactivating aerobic respiration. This can be accomplished by means of hyperbaric oxygen 170 
treatment (HBOT) (100% O2, 2.8 bar), which may be an effective adjuvant for the eradication 171 
of chronic Pa infections (Figure 2) [46,47].  172 
Denitrification is a central process in Pa for another significant reason. A key toxic intermediate 173 
of this pathway, nitric oxide (NO), has been established as one of the key signals which lead 174 
to Pa biofilm dispersal [48,49]. These dispersed cells leave the biofilm to colonize new 175 
locations, contributing to acute virulence and chronic persistence [50,51]. Indeed, a nitrate 176 
reductase mutant (∆nirS) which cannot generate metabolic NO was found to be incapable of 177 
dispersal in the presence of nitric oxide generators [52,53]. It has also been noted that 178 
dispersed cells, removed from the protection of biofilm growth, are substantially more sensitive 179 
to antimicrobial intervention [52]. NO-donors, such as NO-releasing alginates or the 180 
prodrug  DEA-C3D (‘DiEthylAmin-Cephalosporin-3′-Diazeniumdiolate’), co-administered with 181 
antibiotics form a promising new adjunctive therapeutic strategy to combat infection [54,55]. 182 
Pa anaerobic metabolism can also be stimulated by either adding an electron acceptor that 183 
permits denitrification, or by adding arginine, which can be fermented by Pa. This may also 184 
present a potent antimicrobial strategy as both arginine and nitrate were shown to enhance 185 
the killing of Pa by ciprofloxacin and tobramycin under anaerobic, but not aerobic, growth 186 
conditions [56]. It may be possible to inhibit the ability of Pa to activate the denitrification 187 
machinery, blocking its transition into an anaerobic lifestyle. In addition, the handling of toxic 188 
endogenous NO is a carefully orchestrated process in Pa, which may provide a new 189 
antimicrobial opportunity (Figure 1A) [57]. Recent work has provided detailed structural and 190 
mechanistic insight into how these enzymes operate and may catalyse antimicrobial design 191 
targeting this pathway [58–60].  192 
Central carbon metabolism during infection  193 
Central carbon metabolism and associated nutrient assimilation pathways may also be a key 194 
target in the fight against infection (Figure 1C). Pa has a remarkable ability to consume 195 
available nutrients and to survive in a variety of challenging environments. These attributes 196 
may also play a key role in Pa outcompeting rival pathogens in a variety of infection sites 197 
[61,62]. Central carbon metabolic nodes and nutrient uptake systems are extensively 198 
modulated during growth in diverse infection sites (the metabolic requirements of Pa during 199 
CF infection have been reviewed in reference [31]).  200 
In general, the expression of Pa central carbon metabolic pathways is lower in human infection 201 
(both soft-tissue wounds and CF lungs) in comparison with in-vitro growth. Processes such as 202 
ATP synthesis, coupled electron transport, amino acid biosynthesis, propionate metabolism, 203 
oxidative phosphorylation, and phospholipid metabolism were shown to be down regulated in-204 
vivo compared to laboratory conditions. This reflects a concerted effort to reduce cellular 205 
activity and slow growth in-vivo [31,63]. Expression of the genes coding for most of the TCA 206 
cycle (including citrate synthase, aconitate synthase, both isocitrate dehydrogenases, and 207 
oxoglutarate dehydrogenase) were found to be repressed in-vivo. In contrast, isocitrate lyase 208 
(aceA) expression, which transforms isocitrate into glyoxylate, was increased in the human 209 
CF samples, indicating a switch of carbon flux towards the glyoxylate shunt rather than to the 210 
decarboxylation steps of the TCA cycle (Figure 2). AceA expression was also significantly 211 
increased on the protein level for the CF samples in a separate study [13]. The glyoxylate 212 
cycle is also required for the degradation of purified mucins, the major macromolecular 213 
constituents of the mucus layer [27]. The reduced in-vivo expression of pyruvate 214 
dehydrogenase and pyruvate carboxylase which feed pyruvate into the TCA cycle suggests 215 
that Pa employs a gluconeogenic rather than a glycolytic configuration during human infection 216 
[10]. Expression of fumarate hydratase (fumC1), which catalyses the reversible conversion 217 
of fumarate to malate and modulates redox balance, was increased in both transcriptomic and 218 
proteomic profiles for the CF lung infection, but not the soft tissue wound infection. This 219 
observation is consistent with the presence of a series of redox stresses in the lung 220 
environment. Long-chain fatty acid catabolism, notably the genes faoA and faoB, were 221 
previously shown to be required in both murine surgical wound and burn wound infection 222 
models. These genes were also induced in the human soft tissue wound samples [10,11,23]. 223 
Sputum from patients with CF has been shown to contain millimolar concentrations of lactate. 224 
There is an extensive redundancy at this metabolic node as Pa is known to produce four 225 
enzymes annotated as lactate dehydrogenases. LdhA, which reduces pyruvate to d-lactate 226 
during anaerobic survival, LldE and LldD, which oxidize d-lactate and l-lactate, respectively, 227 
during aerobic growth and the newly annotated LldA, which performs redundant l-lactate 228 
oxidation during growth in aerobic cultures [14,64]. As expected, lldA was highly expressed in 229 
the CF samples. Interestingly, this gene also increased substantially in the wound samples 230 
[10,65].  231 
Reactivating cellular respiration 232 
Antibiotic efficacy is intimately linked to bacterial cellular respiration (Figure 2). It has been 233 
established that a reduced susceptibility to bactericidal antibiotics with different modes of 234 
action is coupled with a reduced flux through the TCA cycle, by downregulating TCA cycle 235 
genes and/or by reducing the levels of metabolites feeding into the TCA cycle. These 236 
metabolic adaptations lead to a reduced proton motive force (PMF), limiting the influx of 237 
antibiotics into the cell. In addition, these metabolic adaptations are frequently shown to 238 
reduce intracellular levels of ROS, which likely contributes to increased survival (Figure 2B) 239 
[66]. Meylan et al. demonstrated that supplementation with metabolites from the lower part of 240 
the TCA cycle (fumarate, succinate) and metabolites from lower glycolysis (pyruvate) 241 
sensitized Pa cells to tobramycin. Conversely, upper TCA metabolites, such as citrate, had 242 
little effect. In contrast, glyoxylate supplementation was shown to protect against tobramycin, 243 
conceivably by inhibiting α-ketoglutarate dehydrogenase and redirecting isocitrate into the 244 
glyoxylate shunt. It was finally shown that fumarate enhances the activity of the ETC by 245 
boosting the expression of the TCA cycle and ETC genes, leading to increased respiration, 246 
increased PMF, and increased tobramycin uptake [67,68]. Mammals may use a similar 247 
approach to potentiate antimicrobial efficacy. Lung epithelial cells cultured in a three-248 
dimensional cell-culture model were shown to secrete endogenous metabolites (succinate and 249 
glutamate), which in turn potentiated the bactericidal activity of aminoglycosides against Pa. 250 
Biochemical and phenotypic assays indicated that the epithelial cell conditioned medium 251 
stimulated the PMF of Pa, resulting in increased intracellular pH [69]. This suggests that the 252 
stimulation Pa metabolism and respiration by carbon flux-altering metabolites could be a 253 
promising future strategy.  254 
The TCA cycle is an understudied target in the development of novel therapeutics to 255 
combat Pa. It may be possible to target specific enzymes in central metabolism to boost 256 
aerobic respiration and antibiotic efficacy. The triosephosphate isomerase TpiA reversibly 257 
converts glyceraldehyde 3-phosphate to dihydroxyacetone phosphate, a key step connecting 258 
glucose metabolism with glycerol and phospholipid metabolism (Figure 1C). Deletion of 259 
tpiA from Pa enhances central carbon metabolism, respiration, and oxidative phosphorylation, 260 
which in-turn increases the PMF and promotes the uptake of aminoglycoside antibiotics [70]. 261 
Natural or synthetic inhibitors of the TCA cycle may also have significant potential. The natural 262 
product promysalin, originally isolated from the rhizosphere, exhibits narrow-spectrum 263 
antibacterial activity against Pa. Using affinity-based protein profiling, succinate 264 
dehydrogenase (Sdh) was identified as the biological target of the natural product. This was 265 
further validated through the selection and sequencing of a resistant mutant [71]. However, 266 
based on the strategy of boosting cellular respiration outlined above (Figure 2), 267 
 it is possible that promysalin may drive Pa into a low metabolic state if applied incorrectly, 268 
reducing antibiotic efficacy. Promysalin and other inhibitors which specifically target essential 269 
metabolic enzymes in Pa will be invaluable for testing the feasibility of the carbon flux re-270 
routing strategies described above.     271 
An additional layer of complexity in targeting Pa metabolism is its high intrinsic mutation rate, 272 
leading to rapid phenotypic reorganisation, persistence, and the loss-of-function of numerous 273 
traits which are dispensable in the chronic infection site. These mutations, leading to slow 274 
growth and increased biofilm formation, are a significant issue and dramatically reduce the 275 
efficacy of current antimicrobial strategies [4]. Is it possible to ‘reactivate’ these slow growing, 276 
adapted Pa isolates using the strategies outlined to boost conventional antimicrobial 277 
treatments? Future work will be necessary to elucidate this.   278 
Finding the off switch for infection: targeting Pa virulence factors 279 
Pa infects and disseminates within hosts using a multitude of virulence factors, including the 280 
type III and IV secretion systems, cyanide, pyocyanin, and proteases. Although virulence 281 
factors are host and site specific, several of these virulence factors appear to be crucial for 282 
human infection. It is also likely that important Pa virulence factors remain uncharacterised. 283 
For example, Filamentous bacteriophage (Pf phage) has only recently been appreciated as a 284 
potential therapeutic target for the treatment of chronic Pa infections. CF patients who tested 285 
positive for Pf phage were more likely to have chronic infection and had greater declines in 286 
pulmonary function during exacerbation. Pf phage also promoted antibiotic resistance and 287 
interacted with the mammalian immune system [72–74]. For this reason, targeting the 288 
synthesis of virulence factors by an “antivirulence strategy” represents a promising alternative 289 
to antibiotic therapy. 290 
Communication is key – quorum sensing  291 
The cell-cell communication system known as quorum sensing (QS) regulates the expression 292 
of several key virulence factors in Pa. QS occurs when a critical cell density (or quorum) is 293 
reached as relayed through the production of small molecules known as autoinducers. These 294 
autoinducers are released into the extracellular matrix and are generally recognized by the 295 
same species triggering a collective response such as biofilm formation or virulence (Figure 296 
3). The QS autoinducer molecules used by several Gram-negative bacteria, including Pa, are 297 
acylated homoserine lactones (AHLs). As QS activates a wealth of pathogenic weapons, 298 
unsurprisingly, QS mutants have reduced virulence in several animal models. Pyocyanin, the 299 
terminal signalling molecule in the QS network, is one of the most prominent virulence factors 300 
released by Pa during acute and chronic infections [75,76]. Although this phenazine was noted 301 
earlier as an electron carrier important for respiration, this redox‐active blue pigment also has 302 
cytotoxic and immunomodulating properties. Moreover, it has been demonstrated that 303 
pyocyanin promotes the development of a pulmonary pathophysiology in mice which may 304 
have parallels to the lung of infected cystic fibrosis patients [77] 305 
As summarised in Figure 3, the core QS network of Pa is extensive and exhibits crosstalk at 306 
multiple levels. LasR, the master QS signal receptor, was initially hailed as the main anti-307 
virulence target for Pa and became a key target in small-molecule inhibitor screens. 308 
Subsequent work showed that many patients harbour lasR mutants. The reason for this is still 309 
unclear, but it may involve a combination of “QS cheating” and increased microoxic fitness of 310 
this mutant [78,79]. Although initially discouraging, further investigation showed that most 311 
LasR mutant isolates have rewired their communication circuitry to place the lesser studied 312 
Rhl system at the top of the QS hierarchy (Figure 3). Precisely how this rewiring occurs, and 313 
its consequences for infection, are under active investigation [80–82]. 314 
For the reasons outlined above, a RhlR inhibitor or an inhibitor that simultaneously targets 315 
both RhlR and LasR might be an appropriate therapy for Pa infection. Such a compound has 316 
been synthesized: meta-bromo-thiolactone (mBTL), an analog of the native RhlR autoinducer 317 
BHL (N-butanoyl-L-homoserine lactone). mBTL represses expression of the genes encoding 318 
pyocyanin, prevents biofilm formation, and protects human lung epithelial cells from killing by 319 
Pa (Figure 3). Both the LasR and RhlR quorum-sensing receptors are inhibited by mBTL; 320 
however, it appears that RhlR, not LasR, is the relevant in-vivo target. [81]. Pushing these 321 
designs forward, the molecular nature of RhlR activation is also being examined through the 322 
design of hybrid AHL analogs with structures which merge features of reported lead RhlR 323 
ligands and head groups with improved hydrolytic stabilities [83]. In addition to blocking 324 
virulence, targeting RhlR may lead to metabolic suicide of Pa in the low oxygen lung 325 
environment. It was shown that bacteria lacking RhlR succumb via metabolic NO intoxication 326 
due to dysregulatory increases in nitrate reductase (NAR) and nitrite reductase (NIR) activities. 327 
This imbalance is thought to result in the generation of intracellular NO faster than the 328 
protective nitric oxide reductase (NOR) enzyme can detoxify this potent intermediate (Figure 329 
1B). Thus, the Rhl QS circuit and critical components of anaerobic respiration could be targets 330 
for the killing of Pa anaerobic biofilm in CF lung disease [39].  331 
Other prospects also exist to target the Pa QS system. The LysR-type transcriptional regulator 332 
protein PqsR (or MvfR) is a key component of the alkyl-quinolone (AQ)-dependent QS system 333 
in Pa (Figure 3). Consequently, PqsR could potentially block virulence in this organism [84,85]. 334 
In contrast to RhlR inhibitors, the design of and development of PqsR inhibitors has been 335 
aided by high-resolution structural data of this key QS regulator [85,86]. This has facilitated 336 
the guided optimisation of PqsR inhibitors, such as M64, through target-driven approaches 337 
[87]. Though a surprising strategy, the introduction of flexible linkers rather than rigid motifs 338 
led to a boost in PqsR inhibitor activity and anti‐virulence potency. These recent advances 339 
have led to the discovery and optimization of 2‐amino‐pyridines as promising new PqsR 340 
inhibitors [88]. An additional component of the quinolone system, the thioesterase PqsE, is 341 
also a vital component of the overall Pa QS system, making this enzyme an attractive target. 342 
Several groups are working on inhibitors of this QS node [89–91]. However, it has been noted 343 
that the thioesterase activity of PqsE itself does not appear to be responsible for the QS 344 
signalling properties of this enzyme [92]. Promising recent leads include as a series of 2-345 
(phenylcarbamoyl)benzoic acid inhibitors that noncompetitively inhibit PqsE. However, future 346 
optimisation will be necessary to obtain in-vivo PqsE inhibitory activity [93].  347 
Challenges with targeting quorum sensing 348 
Like with all strategies, drawbacks exist when attempting to exploit the QS system in Pa. In 349 
recent years, QS research has demonstrated that these systems are intricately complex and 350 
have a high degree of plasticity. Our understanding of QS crosstalk in Pa is constantly 351 
evolving, with on-going revisions on which nodes are central and the best intervention 352 
strategies to target this system [90,94–98]. It is possible that QS inhibition may not be the best 353 
approach to curb Pa virulence; the small-molecule activation of RhlR can reduce pyocyanin 354 
production, possibly through a RhlR-mediated suppression of PQS signalling [99]. In addition, 355 
partial agonism of RhlR can reduce virulence in a C. elegans infection model [81]. These non-356 
native ligands may have the potential to upregulate QS to promote the premature dispersal of 357 
biofilms, rendering Pa more susceptible to conventional antibiotic therapies. Finally, although 358 
QS inhibitors have significant potential to block infection at numerous sites, knowing which 359 
infections to target with a QS inhibitor is extremely important. For example, QS is an important 360 
factor in controlling Pa virulence in burn wounds, but not in chronic wounds [100]. Therefore, 361 
QS inhibitors targeting Pa in chronic wound infections may ultimately prove ineffective. This 362 
indicates that further basic research will be necessary to understand the importance of QS in 363 
specific infection sites in order to maximise their efficacy. 364 
The Type III Secretion System injectisome  365 
Pa and many other gram-negative bacteria utilize a complex type III secretion system (T3SS) 366 
to inject effector proteins into host cells. This highly regulated apparatus is comprised of over 367 
20 proteins, which assemble a complex syringe-like machinery spanning from the inner 368 
bacterial membrane, through the extracellular space, and into the host cell membrane. There 369 
are four distinct exoenzymes that Pa injects into the target host cell via the T3SS: ExoT, ExoU, 370 
ExoS, and ExoY [23,26,101]. The T3SS appears to be a central determinant in human 371 
infection by Pa. In support of this, genes which encode components of the T3SS were 372 
significantly upregulated in an ex-vivo explanted CF lung transcriptome study when compared 373 
to in-vitro growth [12]. Additionally, the injection of ExoS or ExoU into phagocytes is critical for 374 
pathogenesis in a murine acute pneumonia model [102]. On top of this, exoenzyme specific 375 
differences appear to be prognostic in infection outcomes. In comparison to strains expressing 376 
ExoS, ExoU-expressing Pa has been associated with more severe outcomes in keratitis, acute 377 
pneumonia, and intensive care unit acquired pneumonia [103,104] 378 
Given its contribution to clinical severity, therapeutic targeting of T3SS or its effectors may 379 
attenuate the morbidity and mortality of acute Pa infections. Several avenues to block T3SS 380 
are currently being explored [105]. These include MEDI3902, a bispecific human monoclonal 381 
antibody that binds to both the PcrV protein involved in host cell cytotoxicity and Psl 382 
exopolysaccharide involved in Pa colonization and tissue adherence. This antibody is 383 
currently undergoing a phase 2 proof-of-concept study (NCT02696902) for the prevention of 384 
nosocomial pneumonia caused by Pa in high-risk patients [106]. It may also be possible to 385 
inhibit assembly of the T3SS needle by disrupting interactions between the needle subunits, 386 
thereby blocking exoenzyme release. Ngo et al. identified compounds inhibiting the protein–387 
protein interaction between PscE and PscG, the two cognate chaperones of the needle 388 
subunit PscF of the T3SS. Two promising candidates from these small molecule library 389 
screens specifically inhibited the T3SS and reduced the ex-vivo cytotoxicity of bacteria and 390 
their virulence in a Galleria mellonella infection model [107].  391 
As with many virulence factors, targeting T3SS may only be a viable strategy at specific Pa 392 
infection stages or sites [23,26]. T3SS-negative bacteria have been isolated from non-CF 393 
patients with acute infections. Likewise, although initial Pa infections in patients with CF are 394 
associated with T3SS-positive strains, T3SS-negative strains are isolated with increasing 395 
frequency from chronically infected CF patients over time. This may be explained by cheating 396 
strategies employed by Pa to exploit the production of public goods. Indeed, a new taxonomic 397 
group has recently emerged from analysis of the Pa pangenome, characterized by major 398 
alterations in their virulence factor repertoire; including the absence of T3SS effectors and the 399 
associated secretion and regulatory machinery. This suggests that some Pa strains could be 400 
inherently resistant to this anti-virulence strategy [9]. It is likely that other virulence factors, 401 
such as quorum sensing, play a larger role in these cases [108,109] 402 
Pa surface colonization and aggregation 403 
Host cell membranes and cell surfaces are the first line of defence against bacterial invasion. 404 
Pa has evolved several surface colonisation strategies in order to attack host cells and secure 405 
nutrients or to develop biofilms to shield itself from the surrounding environment. Biofilm 406 
formation by Pa is hypothesized to follow a developmental programme involving three discrete 407 
steps: surface attachment, microcolony formation and then maturation into an antibiotic‐408 
resistant population encased in an extracellular polymeric matrix.  409 
In the initial stages of surface attachment, Pa uses fiber-like appendages called type IV pili 410 
(TFP) to sense contact with surfaces. This activates a signaling cascade, resulting in the 411 
expression of a plethora of genes associated with pathogenicity and twitching motility. TFP 412 
also mediate virulence through the coordinated and mutually dependent action with T3SS to 413 
facilitate exoenzyme injection into host cells. TFP and twitching were both required 414 
for pathogenicity in a murine model of corneal infection, specifically these features were 415 
required for Pa to traverse human corneal epithelial multilayers, and efficiently exit invaded 416 
epithelial cells [110–113]. Pa must respond in a rapid and orchestrated manner to ensure 417 
successful colonisation. Recent work is providing mechanistic insight into this fine balance of 418 
virulence, proliferation, and dissemination behaviours. Upon surface contact, the 419 
concentration of the second messenger c-di-GMP increases within seconds. This leads to 420 
surface adherence and virulence induction by stimulating pili assembly through activation of 421 
the c-di-GMP receptor FimW. These surface-attached bacteria then divide asymmetrically to 422 
generate a piliated subpopulation committed to microcolony formation (striker) and a 423 
flagellated, motile offspring that explores the surface (spreader). Cell differentiation is driven 424 
by a cyclic nucleotide phosphodiesterase which asymmetrically positions to the flagellated 425 
pole, maintaining low c-di-GMP levels in the motile offspring. This cellular asymmetry program 426 
was shown to boost enhance spread and tissue damage [114]. In addition, Armbruster et al. 427 
found that the Wsp chemosensory surface sensing system generates heterogeneity in surface 428 
sensing, resulting in the two physiologically distinct subpopulations of cells [115]. It has also 429 
been shown that surface-associated Pa induces LasR QS targets more intensely in response 430 
to autoinducer signalling molecules in comparison to planktonic cultures. TFP retraction 431 
motors and the minor pilins are thought to play a role in this process. Thus, bacteria use pili 432 
not only to attach and move, but also to sense their environment and regulate surface-433 
associated cellular processes. The coupling of physical surface responses and chemical QS 434 
responses in this manner may enable Pa to hyper-activate community behaviours when they 435 
are more beneficial [116]. 436 
Bacterial flagellar motility is a fundamental mechanism exploited by host phagocytes to enable 437 
recognition and ingestion of bacteria. Correspondingly, loss of bacterial motility (which is 438 
consistently observed in clinical isolates from chronic Pa infections), enables bacteria to 439 
evade immune cells. Lorenz et al. have shown that surprisingly, flagellin appears to be an 440 
important factor also for survival of the ΔlasR mutant during chronic biofilm‐associated 441 
infections [117,118]. During chronic infection in the CF lung Pa appears to persist in immotile 442 
aggregates. Surrounding immune cells (polymorphonuclear leukocytes) may constrain the 443 
growth of Pa through aerobic respiration, rewiring Pa towards anaerobic respiration [119–121]. 444 
The exact mechanisms producing aggregation remain unclear, but entropic forces generated 445 
by local polymers and macromolecules present at chronic infection sites (mucin, DNA, F-actin, 446 
etc.) may facilitate cell aggregation by a passive mechanism known as “depletion aggregation” 447 
[122]. 448 
Most Pa anti-virulence strategies require a detailed structural and mechanistic dissection of 449 
the target in question to develop an effective strategy for inhibition. An exciting way to inhibit 450 
Pa surface colonisation may be through a bottom-up approach via the combinatorial discovery 451 
of polymers resistant to bacterial attachment. Hook et al. screened hundreds of polymeric 452 
materials in a high-throughput microarray format to identify polymers that reduce the surface 453 
attachment of pathogenic bacteria including Pa [123]. This strategy has also led to the 454 
development of a predictive quantitative structure–activity relationship (QSAR) model to 455 
predict bacterial biofilm formation on a range of polymers which were not included in the initial 456 
library. Predictions were validated through the design of new coatings found to be resistant to 457 
biofilm formation [124]. These materials have the potential to revolutionise the design of biofilm 458 
resistant medical devices.  459 
It has been established that the dispersal of biofilm microbes into their planktonic form 460 
increases their susceptibility to antimicrobials. While biofilm degrading and dispersing agents 461 
may represent attractive adjunctive therapies for biofilm-associated chronic infections, 462 
Fleming et al. have shown that a sudden dispersal of biofilm cells can be detrimental to the 463 
host. They found that large-scale, in-vivo dispersal of motile biofilm bacteria by glycoside 464 
hydrolases caused lethal septicaemia in a mouse wound model in the absence of antibiotic 465 
therapy. However, when administered cautiously, dispersal agents may increase the efficacy 466 
of current antimicrobial therapies [125]. 467 
Understanding and altering how Pa virulence programs are activated. 468 
The concept of virulence factor inhibition as an antimicrobial strategy is typically pursued 469 
through the development of targeted ‘antivirulence’ drugs which block specific effectors or 470 
associated global regulators. It is often proposed that such treatments exert weaker selection 471 
for resistance than conventional antibiotics, based on the idea that these actions disarm rather 472 
than kill directly. However, the evolutionary robustness of antivirulence drugs is still debated 473 
[126,127]. An alternate antivirulence strategy may be to target how pathogenic ‘virulence 474 
programs’ are activated. By understanding how environmental cues elicit virulence activation 475 
in specific infection sites, it may be possible to manipulate these innate reactions to change 476 
how Pa behaves in-vivo. Several examples of this approach exist in the literature, suggesting 477 
that the creation of microenvironmental conditions that suppress virulence is a feasible 478 
strategy. 479 
Nutrient availability has long been established as a means to modulate bacterial behaviour. 480 
Phosphate (Pi) depletion develops rapidly following major surgery or organ injury and can be 481 
used to predict the development of lethal sepsis. Pa senses this reduction in phosphate as an 482 
environmental cue for enhanced virulence in-vitro and lethality in-vivo. Building on this 483 
discovery, intestinal phosphate supplementation may be a novel strategy to contain pathogens 484 
associated with lethal gut-derived sepsis. In fact, phosphate crosslinked nanoparticles that 485 
result in sustained delivery of Pi  were effective compounds for suppressing virulence 486 
activation in Pa in-vitro [128–131].  487 
Another key nutrient, L-arginine (L-Arg), was shown to be significantly depleted in burn 488 
wounds when compared to non-inured tissue. This is a result of elevated arginase production 489 
by myeloid-derived suppressor cells, which are recruited to the site of injury in response to 490 
inflammation. L-Arg is a potent chemoattractant for Pa, with low concentrations leading to 491 
increased motility. Indeed, topical administration of L-Arg resulted in reduced Pa motility and 492 
enhanced biofilm formation, which translated to decreased Pa spread and increased animal 493 
survival in infection models. This suggests that the development of an arginine-based topical 494 
treatment has the potential to reduce the spread of infection and aid patient recovery 495 
[132,133]. Further work is warranted in order to uncover additional nutrient cues at the site of 496 
infection which can modulate Pa virulence.  497 
Host factors also have a clear influence on Pa behaviour during infection. QS is inhibited by 498 
physiological levels of serum albumin, which sequesters homoserine lactone quorum signals 499 
(3-oxo-C12-HSL), suppressing the ability of Pa to produce QS controlled virulence factors. As 500 
QS is an important factor controlling virulence in burn wounds, the local administration of 501 
exogenous albumin may attenuate Pa virulence [134]. The biological hydrogel mucus, 502 
consisting of biopolymers called mucins, has also been recognised to play a role in host-503 
microbe interactions. Mucin is also the primary polymer in CF sputum which impacts on the 504 
diffusion of QS signalling molecules [135,136]. When Pa is exposed to native mucus, this 505 
triggers downregulation of virulence genes that are involved in QS (lasR), siderophore 506 
biosynthesis (pvdA), and the T3SS (pcrV). Purified mucins also mediated biofilm dispersal by 507 
a mechanism dependent on an intact flagellum. Extraordinarily, glycans isolated from the 508 
mucin backbone can regulate these bacterial phenotypes, even at relatively low 509 
concentrations. Thus, it may be possible to use purified mucin glycans to lessen Pa virulence, 510 
rendering it less harmful to the host [137].  511 
The modulation of Pa central metabolism dynamics may be another opportunity to curb 512 
virulence. Using fluorescence lifetime imaging microscopy (FLIM), which reports the activity 513 
of NADH in live cells, Perinbam et al. reported that a shift in central metabolism accompanies 514 
virulence activation in Pa. Rewiring surface-attached Pa central metabolism with citrate and 515 
pyruvate supplementation decreased the enzyme-bound NADH pool, reduced total NAD(H) 516 
production, and abolished Pa host-killing activity. In contrast, glucose and glycerol addition 517 
had little impact on host-killing activity. It was also possible to induce Pa virulence at an earlier 518 
time using the ETC oxidase inhibitor, antimycin A. This suggests that the glyoxylate cycle 519 
bypass (Figure 1C) may be involved in the virulence activation of surface-attached 520 
populations, as flux thorough this metabolic node may be inhibited by citrate or pyruvate 521 
[138,139].  522 
Barriers to success: what knowledge limitations are holding us back?  523 
Which Pa strain should I use?  524 
Pa strain selection is an important factor when it comes to unravelling infection mechanisms. 525 
PAO1 and PA14 are arguably the most common laboratory-adapted Pa research strains which 526 
are used worldwide [140,141]. Although these two strains have undoubtedly catalysed our 527 
understanding of Pa biology, ignoring their limitations may also be holding us back from future 528 
advances.  529 
The microevolution of individually maintained sublines of PAO1 has resulted in significant 530 
phenotypic variability and the altered production of key secreted factors (rhamnolipid, 531 
pyoverdine, pyocyanin, PQS, exopolysaccharide). It is likely that small alterations exist within 532 
PAO1 and PA14 strains held in laboratories across the world. These changes may potentially 533 
affect the outcomes of in-vitro phenotypic analyses and in-vivo pathogenesis studies [140]. In 534 
a recent transposon sequencing study using nine different Pa isolates (including five from 535 
various human infection sites), the laboratory strain PA14 was an outlier in two growth 536 
conditions, M9 minimal media and urine. In these two media, PA14 had more essential genes 537 
involved in oxidative phosphorylation and the TCA cycle when compared to the other isolates. 538 
This behaviour could be a consequence of PA14 microevolution to laboratory conditions, 539 
highlighting the risks of extrapolating PA14 behaviour to the species in general [24]. There 540 
also appears to be lineage specific differences in key Pa pathogenicity determinants. 541 
Evaluation of the reversible attachment regime for PAO1 and PA14 suggest the existence of 542 
two distinct surface colonization strategies. PAO1 lineages appear to commit quickly to a 543 
surface when compared to PA14 lineages. These differences may be explained by 544 
modifications of their corresponding Wsp-based and Pil-Chp-based surface-sensing systems 545 
[142]. A simple solution to this strain issue is to increase the use of Pa clinical isolates for 546 
infection-site specific analyses; however, these strains can be challenging to work with 547 
because of inherent growth defects or issues with genetic tractability. As per the reversible 548 
attachment study [142], a solution may lie in examining multiple laboratory strains 549 
simultaneously when elucidating core mechanisms. This will also unravel strain specific 550 
attributes and increase our knowledge of strain divergence.   551 
All models are wrong, but some are useful: recapitulating Pa infection 552 
A variety of laboratory models are available to study Pa infection, each with their own 553 
advantages and disadvantages. As with strain choice, poor infection model choice can lead to 554 
inconsistent or opposing studies, including virulence factor importance or antimicrobial 555 
efficacy during infection. This in turn can lead to erroneous results in drug development or 556 
synergy studies [143]. This issue is compounded by the fact that current preclinical animal 557 
models do not satisfactorily predict the complexities of human respiratory disease, further 558 
endangering the success of antimicrobial drug efficacy testing [144]. In addition, experimental 559 
protocols when using infection models, such as inoculum CFU or immunosuppression 560 
regimen, are not universally standardized or reported. The introduction of minimum 561 
information guidelines, as recently introduced for in-vitro biofilm formation assays, may help 562 
to alleviate this issue [145].  563 
A stark example of changes in Pa phenotypes and behavior when grown in different model 564 
systems is apparent in relation to glycoside hydrolase activity. These enzymes are known to 565 
cause the dispersal of Pa from biofilms into a free-swimming state, increasing antimicrobial 566 
efficacy. Several strains of Pa biofilms were grown in-vivo (in a mouse model of wound 567 
infection) and then excised and treated ex-vivo. These same strains were also grown as an 568 
in-vitro biofilm for comparison. Surprisingly, the biofilms that had the greatest dispersal 569 
response when treated ex-vivo were those for which the in-vitro treatments had the least 570 
effect. This highlights the possibility that effective approaches for biofilm eradication may 571 
depend strongly on the growth environment, stressing the need for taking growth conditions 572 
into account when devising antibiofilm strategies [146].  573 
Recent work is applying machine learning approaches to optimise and evaluate the quality 574 
of models to recapitulate Pa infection sites. This work uncovered that the in-vitro synthetic CF 575 
sputum medium model and a CF airway epithelial cell model had the highest genome-wide 576 
accuracy when attempting to recreate the Pa transcriptomic signature during CF lung infection. 577 
Nevertheless, these models still underperformed on distinct categories, including porins and 578 
polyamine biosynthesis for the synthetic sputum medium and protein synthesis for the 579 
epithelial cell model. Interestingly, over 200 genes that were not mimicked in a Pa model strain 580 
were largely captured by using a clinical isolate, illustrating the limitations of laboratory strains 581 
[147]. This evidence-based method of selecting and improving laboratory models is a move in 582 
the right direction. Paradigm shifts need to occur in assessing a variety of Pa infection sites, 583 
particularly chronic wounds and burns [148]. Using metabolomic and transcriptomic data from 584 
infection sites as a reference point, the challenge ahead will be to empirically develop 585 
reproducible models to mimic these environments. This may be aided by the inclusion of 586 
additional variables such as polymicrobial communities, therapeutics, and reproducible spatial 587 
structure.  588 
Knowledge gaps in Pa infection biology 589 
While the above studies have proposed several new approaches to combat infection, there 590 
are still significant gaps in our understanding of Pa infection biology. It’s important to note that 591 
although the in-vivo Pa omics data have provided a snapshot of a largely advanced stage of 592 
infection, these data do not explain how Pa establishes itself during infection or how it 593 
dominates in various infection sites, eliminating competing pathogens. Many testable models 594 
exist to explain how these processes occur and they are likely to be the focus of further 595 
extensive studies. There is a clear need for greater understanding of the mechanisms 596 
underlying both the initiation of Pa infection and dispersal from established biofilms (for both 597 
acute and chronic infections), as these processes appear to be at the intersection of virulence 598 
and antimicrobial susceptibility. It is also worth noting that the rationale behind several key 599 
metabolic and virulence rearrangements which are known to occur in Pa as it transitions from 600 
an acute to a chronic infection is of significant interest. Additional factors such as spatial 601 
structure and environmental heterogeneity are likely to drive the diversification of Pa within 602 
the infection site. For this reason, it is likely that multiple evolutionary trajectories to 603 
pathoadaptation may exist, complicating an empirical disentanglement of this phenomenon 604 
[149]. 605 
Metabolic flexibility, interconnected nodes and rapid pathway reorganisation through mutation 606 
are major impediments in targeting Pa. The last decade has resulted in unprecedented 607 
developments in our understanding of the complexity and crosstalk within Pa QS systems, 608 
virulence factor production and central metabolism, and systems level interactions across 609 
these key nodes. We need to further refine our understanding of these central targetable 610 
pathways on a systems level in order to screen for inhibitors in-silico [150]. This review has 611 
highlighted a series of core metabolic components in Pa which appear to be crucial for 612 
sustaining infection (Figure 1 – red boxes). If further drug discovery resources are directed 613 
towards modulating these key systems, it is likely to yield effective antipseudomonal therapies. 614 
However, in order to fully grasp Pa infection, there must be a directed effort towards strong 615 
functional genomics approaches which will elucidate the precise role of uncharacterized genes 616 
which are essential for Pa growth or virulence during infection. It is likely that in-vitro studies 617 
which neglect the importance of polymicrobial interactions, in-vivo stresses or genetic 618 
mutation are only allowing us to grasp a fraction of Pa physiology, masking the importance of 619 
infection-relevant genetic networks. The clear importance of polymicrobial interactions on Pa 620 
physiology during infection have been reviewed elsewhere [151,152].  621 
What technologies will lead these advances? Machine learning will undoubtedly continue to 622 
play a large role in future leaps in understanding Pa infection [10,153,154]. Developments in 623 
structural biology are also providing new mechanistic insight into how Pa develops resistance 624 
to current therapies. The cryo-electron microscopy (Cryo-EM) structures of the Pa ribosome 625 
and a uL6 mutant ribosome from a CF isolate were recently elucidated. The uL6 deletion 626 
causes resistance to members of the aminoglycoside family of antibiotics, ribosomal 627 
instability, and a reduced growth rate. The structural data have offered explanations for these 628 
phenotypic alterations and will act as a template for unravelling the consequences of ribosomal 629 
variant strains obtained during infection [155]. Understanding drug resistance on a molecular 630 
level may then enable rapid screening approaches for personalized therapies. Although 631 
sequencing technologies will continue to play a large role in driving Pa biology forward, the 632 
combined use of other technologies, such as microscopy, machine learning, mass 633 
spectrometry, structural biology, and non-invasive metabolic sensors will be essential to 634 
catalyse future research advances. 635 
Concluding remarks 636 
Tremendous progress has been achieved in understanding Pa infection, however, there are 637 
still many open questions to be answered. The large-scale testing and validation of new 638 
antimicrobial therapies is ongoing, but it is likely that we’re beholden to the therapies that we 639 
have now for the foreseeable future. For this reason, enhancing the efficacy of current 640 
antimicrobial therapies by the potentiation of cellular respiration (hyperbaric oxygen treatment, 641 
metabolic activators), or through biofilm dispersal strategies (NO generators, glycoside 642 
hydrolases) may be the easiest road forward. Virulence reduction strategies targeting QS, 643 
T3SS and Pa attachment hold promise as adjuvants and may offer a new path for narrow 644 
spectrum therapies against multidrug-resistant clinical isolates. Although strategies targeting 645 
core metabolism or virulence appear as separate entities in this review, the extensive crosstalk 646 
between these systems makes the specific targeting of any one system extremely difficult in 647 
this organism.  648 
Carle Gessard’s interest in Pa was piqued over 130 years ago by its “radiant blue/green 649 
secretions” (pyocyanin) and its ability to grow “equally well in saliva, perspiration, albumin, 650 
blister fluid and liquid from hydroceles” [156]. We now appreciate that combatting this 651 
pathogen will depend on exploiting this metabolic flexibility and its ability to synthesise these 652 
potent virulence factors. The above research directions have taken us closer to accomplishing 653 
this aim. It is clear that it will be a hard-won war, but each battle brings its own new and 654 
interesting challenges which make for rewarding and exciting research. 655 
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Figure Legends 662 
Figure 1: A schematic overview of the interconnected physiologic networks of Pa; 663 
Cellular respiration [A], denitrification [B] and carbon metabolism [C]. Avenues to target 664 
these systems (discussed in the main text) are highlighted with red boxes. Cellular 665 
respiration: Pa encodes a collection of aerobic terminal oxidases (Cco1, Cco2, Cyo, Cox and 666 
CIO) which catalyze electron transfer from the respiratory apparatus to oxygen (cellular 667 
respiration – represented by NADH dehydrogenase (NDH), succinate-Q-reductase complex 668 
(SDH), terminal oxidases and ATP synthase) The different terminal oxidases vary in their 669 
affinities, electron donor (ubiquinol or cytochrome c) and efficiencies. Pa phenazines (such as 670 
pyocyanin) can synergise with these terminal oxidases to confer antibiotic tolerance and aid 671 
in aerobic and anaerobic functionality. Therefore, the Pa terminal oxidases and associated 672 
reactions are a potential antimicrobial target [157]. Increased production of electron donors 673 
increases the proton motive force (PMF), driving metabolism and leading to increased levels 674 
of intracellular reactive oxygen species (ROS). Cell-damaging ROS can be harnessed to 675 
increase the efficacy of antibiotics targeting Pa [158]. Denitrification: The Pa denitrification 676 
pathway is activated in the presence of low oxygen. Here, nitrate (NO3−) is reduced to 677 
molecular nitrogen (N2) in four steps, each catalyzed by a specific reductase, namely, nitrate 678 
reductase (NAR), nitrite reductase (NIR), NO reductase (NOR), and nitrous oxide reductase 679 
(N2OR). Q, coenzyme Q or ubiquinone; QH2, reduced form of ubiquinone [159]. Modulation 680 
key steps of this pathway by using targeted inhibitors and/or selective reductase 681 
overactivation/inhibition can lead to the uncontrolled accumulation of reactive nitrogen species 682 
(RNS), such as nitric oxide (NO) and nitrite (NO2-). These toxic intermediates can potentiate 683 
the efficacy of therapeutic antibiotics. Central carbon metabolism: the Pa central metabolic 684 
network consists of six main metabolic blocks, identified with different colours: (i) the 685 
peripheral pathways, that encompass the oxidative transformation of glucose, acetate, lactate 686 
and glycerol (grey); (ii) the Embden-Meyerhoff-Parnas pathway, orange); (iii) the pentose 687 
phosphate pathway (PPP, green); (iv) the Entner-Doudoroff pathway (EDP, purple); (v) the 688 
tricarboxylic acid cycle (blue) and glyoxylate cycle (red); and (vi) anaplerotic and 689 
gluconeogenic bioreactions (yellow) [15,16]. The first enzyme of the glyoxylate shunt (AceA) 690 
is highlighted. The triosephosphate isomerase TpiA is another validated metabolic target. The 691 
natural product promysalin targets succinate dehydrogenase (SDH), an essential reaction in 692 
Pa carbon metabolism. SDH is also a central ETC component (succinate-Q reductase 693 
complex).  694 
Abbreviations; AcCoA, acetyl-coenzyme A; CIT, citrate; PYR, pyruvate, ICIT, isocitrate; AKG, 695 
alpha-ketoglutarate; FUM, fumarate; MAL, malate; OAA, oxaloacetate; KDPG, 2-keto-3-696 
deoxy-6-phosphogluconate; G3P, glyceraldehyde 3-phosphate; 3PG, 3-phosphoglycerate;  697 
FBP, fructose-1,6-bisphosphate; F6P, fructose-6-phosphate; G6P, glucose 6-phosphate; 698 
DHAP,  dihydroxyacetone phosphate;  6PG, 6-phosphogluconate; Ri5P, ribulose-5-699 
phosphate; R5P, ribose-5-phosphate; X5P, xylulose-5-phosphate; S7P, sedoheptulose-7-700 
phosphate; E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate; ATP, adenosine 701 
triphosphate; ADP, adenosine diphosphate; FMN, flavin mononucleotide; NADH, nicotinamide 702 
adenine dinucleotide; NADPH, nicotinamide adenine dinucleotide phosphate; CO2, carbon 703 
dioxide; QH2, ubiquinol; UQ8H2, ubiquinol‐8; Pi, inorganic phosphate; H+, proton; FADH2, flavin 704 
adenine dinucleotide; H2O, water.  705 
Figure 2: Stimulating metabolic flux drives cellular respiration, which in turn sensitises 706 
Pa to antimicrobial intervention. A; The production of electron donors (NADH, FADH) 707 
stimulates the proton motive force (PMF), which is essential for the uptake of many antibiotics 708 
(tobramycin uptake depicted). This ramp up of metabolism may also lead to increased levels 709 
of intracellular reactive oxygen species (ROS), which potentiate antibiotic efficacy. The uptake 710 
of tobramycin is an energy dependent process that relies on the electron transport chain (ETC) 711 
to maintain a sufficiently high PMF [158]. B; Central metabolism is largely downregulated 712 
during Pa infection, with increased expression of the glyoxylate shunt (red)d, skipping the 713 
decarboxylation steps of the TCA cycle. This reduced cellular respiration and growth 714 
consequently lowers the uptake of PMF dependent antibiotics, such as the aminoglycosides, 715 
increasing tolerance. C; Reactivating Pa respiration in hypoxic Pa aggregates using 716 
hyperbaric oxygen (O2) treatment (HBOT) or metabolic potentiators will then increase cellular 717 
respiration (full TCA cycle flux - green) and the PMF, increasing antibiotic efficacy . B; Central 718 
metabolism is largely downregulated during Pa infection, with increased expression of the 719 
glyoxylate shunt (red), skipping the decarboxylation steps of the TCA cycle. This reduced 720 
cellular respiration and growth consequently lowers the uptake of PMF dependent antibiotics, 721 
such as the aminoglycosides, increasing tolerance. C; Reactivating Pa respiration in hypoxic 722 
Pa aggregates using hyperbaric oxygen (O2) treatment (HBOT) or metabolic potentiators will 723 
then increase cellular respiration (full TCA cycle flux - green) and the PMF, increasing 724 
antibiotic efficacy [160]. 725 
Figure 3: A schematic overview of the Pa quorum sensing network, their respective 726 
signalling molecules and validated inhibition sites.  As the bacterial cell density increases, 727 
QS signalling molecules build-up until reaching a threshold concentration. This accumulation 728 
results in the transcription of genes under QS regulation, activating a battery of virulence 729 
factors. The las system consists of a transcriptional activator, LasR, and the acyl-homoserine 730 
lactone (AHL) synthase, LasI, which catalyses synthesis of the autoinducer N-(3-731 
oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL, also known OdDHL). The 732 
transcriptional regulator RsaL negatively regulates lasI synthesis. This signalling molecule 733 
binds to the transcriptional activator LasR, and the OdDHL-LasR complex then stimulates the 734 
expression of target genes. The rhl system consists of the LuxI type autoinducer synthetase, 735 
RhlI, which synthesises the autoinducer molecule N-butyryl-L-homoserine lactone (C4-HSL, 736 
also known BHL). This signalling molecule binds to the transcriptional activator RhlR, and the 737 
BHL-RhlR complex then stimulates the expression of target genes. The QS inhibitor 738 
compound meta-bromo-thiolactone (mBTL) partially inhibits both LasR and RhlR, blocking 739 
both the production of pyocyanin and biofilm formation. The pqs system (PQS - 740 
Pseudomonas quinolone signal) consists of PqsA-E, PhnAB, PqsH and a LysR family 741 
regulator PqsR. Anthranilate synthesised by PhnAB is processed by the enzymes PqsA to 742 
PqsD to generate 2-heptyl-4-quinolone (HHQ). HHQ is then converted into PQS (2-heptyl-3-743 
hydroxy-4-quinolone) by PqsH. The PQS:PqsR and HHQ:PqsR complexes stimulate the 744 
expression of target genes. A key target in this system, PqsE, is a thioesterase which cleaves 745 
2-aminobenzoylacetyl-CoA, resulting in 2-aminobenzoylacetate, the precursor of HHQ. The 746 
benzamide-benzimidazole compound M64 inhibits PqsR, which in turn interferes with biofilm 747 
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